Multidrug resistance in haematological malignancies.
Many patients with haematological disorders develop resistance to the drugs used in the treatment of their condition. This resistance is often effective against a range of chemotherapeutic agents, hence the term multidrug resistance (MDR) is used. During the past ten years the mechanisms underlying the development of MDR have become better understood, and in this Review the current concepts of the factors contributing to MDR are examined.
Dept of Haematology, Royal London Hospital, Whitechapel, England, UK.
X R
XR
Jiang
M G
MG
Macey
A C
AC
Newland
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004351:Drug Resistance / Q000235:genetics / Q000502:physiology*; D004359:Drug Therapy, Combination; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins